In summary, our research findings have elucidated that VVO treats insomnia through a variety of components and multiple targets, with MAOB, MAOA, SLC6A4, HTR2A, and others at serotonergic synapses playing a vital role in the process of VVO treating insomnia. The gene discussed is HTR2A; the disease is insomnia measurement.